Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.64 |
| ▸ | PGR | P06401 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | SHBG | P04278 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11503559 | 0.85 | NR3C1 (0.64) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| Hydrocortisone Hemisuccinate Anhydrous SCHEMBL12540616 | 0.85 | HIF1A (1.00) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| Hydrocortisone Hemisuccinate Anhydrous SCHEMBL12541145 | 0.85 | HIF1A (1.00) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| Hydrocortisone Hemisuccinate Anhydrous SCHEMBL13960044 | 0.85 | HIF1A (1.00) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| Hydrocortisone Hemisuccinate Anhydrous SCHEMBL10393928 | 0.85 | HIF1A (1.00) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| Hydrocortisone Hemisuccinate Anhydrous SCHEMBL10393930 | 0.85 | HIF1A (1.00) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| Hydrocortisone Hemisuccinate Anhydrous SCHEMBL7664 | 0.85 | HIF1A (1.00) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| SCHEMBL4594076 | 0.84 | HIF1A (0.52) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| SCHEMBL603002 | 0.84 | HIF1A (0.69) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 | |
| Hydrocortisone Hemisuccinate Anhydrous SCHEMBL1320103 | 0.84 | HIF1A (0.98) | HIF1ASMN1; SMN2LMNANR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101677957-A | Polymer formulations for delivery of bioactive agents | CARBYLAN BIOSURGERY INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2111860-A1 | INFLAMMATION INHIBITOR COMPRISING ZINC SALT OF ACYLAMINO ACID | Ajinomoto Co., Inc. (JP) | 2009-10-28 | — | — | EP | disclosed |
| CN-1968690-A | Inflammation inhibitor containing zinc salt of acylamino acid | AJINOMOTO KK (JP) | 2007-05-23 | — | — | CN | disclosed |
| US-20070099888-A1 | Inflammation Inhibitor Comprising Zinc Salt of Acylamino Acid | AJINOMOTO CO., INC. (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099888-A1 | Inflammation Inhibitor Comprising Zinc Salt of Acylamino Acid | NFKBIA, ZNF787, IL17A | HIF1A 2020/4885SMN1; SMN2 4800/4885LMNA 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.